M.H. Cullen

1.7k total citations
27 papers, 1.1k citations indexed

About

M.H. Cullen is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, M.H. Cullen has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Surgery, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in M.H. Cullen's work include Testicular diseases and treatments (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Childhood Cancer Survivors' Quality of Life (4 papers). M.H. Cullen is often cited by papers focused on Testicular diseases and treatments (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Childhood Cancer Survivors' Quality of Life (4 papers). M.H. Cullen collaborates with scholars based in United Kingdom, Belgium and United States. M.H. Cullen's co-authors include A. Horwich, Sally Stenning, S.B. Kaye, M C Parkinson, Pat Cook, G. Read, Sophie D. Fosså, C.M. Woodroffe, Rupert W. Jakes and M.V. Williams and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Allergy and Clinical Immunology.

In The Last Decade

M.H. Cullen

27 papers receiving 1.1k citations

Peers

M.H. Cullen
S. D. Fosså Norway
Farzana Pashankar United States
Torgeir Wethal Norway
Claudio Spinelli Italy
Octavio Castillo Chile
D. Parker United Kingdom
Patton B. Saul United States
Klaus Pietzner Germany
Sumeet Bhatia United States
Thomas A. Rozanski United States
S. D. Fosså Norway
M.H. Cullen
Citations per year, relative to M.H. Cullen M.H. Cullen (= 1×) peers S. D. Fosså

Countries citing papers authored by M.H. Cullen

Since Specialization
Citations

This map shows the geographic impact of M.H. Cullen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.H. Cullen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.H. Cullen more than expected).

Fields of papers citing papers by M.H. Cullen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.H. Cullen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.H. Cullen. The network helps show where M.H. Cullen may publish in the future.

Co-authorship network of co-authors of M.H. Cullen

This figure shows the co-authorship network connecting the top 25 collaborators of M.H. Cullen. A scholar is included among the top collaborators of M.H. Cullen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.H. Cullen. M.H. Cullen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cullen, M.H.. (2012). Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours. Annals of Oncology. 23. x342–x348. 15 indexed citations
2.
Sydes, Matthew R., John Radford, Barry W. Hancock, et al.. (2009). Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Annals of Oncology. 21(3). 568–573. 9 indexed citations
3.
Sydes, Matthew R., et al.. (2008). Myeloablative therapy for recurrent Hodgkin lymphoma: Good success rates irrespective of previous treatments in the UKLG LY09 trial (ISRCTN97144519). ePrints Soton (University of Southampton). 2 indexed citations
4.
Swinson, Daniel, et al.. (2005). Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage III/IV non-small-cell lung cancer. Journal of Clinical Oncology. 23(16_suppl). 7256–7256. 6 indexed citations
5.
Hancock, Bruno C., John Radford, M.H. Cullen, et al.. (2004). Randomised controlled trial of ABVD vs. two multi-drug regimens (MDRs) for advanced Hodgkin's lymphoma (HL): Initial results of UKLG LY09 (ISRCTN97144519).. British Journal of Cancer. 91. 1 indexed citations
6.
Radford, John, M.H. Cullen, Matthew R. Sydes, et al.. (2003). Randomised comparison of ABVD with two multi-drug regimens (MDRs) in the treatment of advanced Hodgkin lymphoma (HL): Initial results of the UKLG LY09 study (ISRCTN 97144519).. Blood. 102(11). 2 indexed citations
7.
Cullen, M.H.. (2001). Pulmonary and respiratory complications of pediatric trauma. PubMed. 7(1). 59–77. 16 indexed citations
8.
9.
Cullen, M.H., et al.. (1996). Management preferences in stage I non-seminomatous germ cell tumours of the testis: an investigation among patients, controls and oncologists. British Journal of Cancer. 74(9). 1487–1491. 29 indexed citations
10.
Cullen, M.H., Sally Stenning, M C Parkinson, et al.. (1996). Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.. Journal of Clinical Oncology. 14(4). 1106–1113. 223 indexed citations
11.
Jones, Simon R. M., et al.. (1996). Alpha-foetoprotein heterogeneity: What is its value in managing patients with germ cell tumours?. Clinical Oncology. 8(5). 323–326. 5 indexed citations
12.
Dockhorn, Robert J., et al.. (1995). Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. Journal of Allergy and Clinical Immunology. 96(1). 50–56. 39 indexed citations
13.
Read, G., Sally Stenning, M.H. Cullen, et al.. (1992). Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.. Journal of Clinical Oncology. 10(11). 1762–1768. 294 indexed citations
14.
Allen, Stephen, et al.. (1991). Assessment of the response to chemotherapy in oesophageal cancer. European Journal of Cardio-Thoracic Surgery. 5(10). 519–522. 16 indexed citations
15.
Woodroffe, C.M., Simon R. M. Jones, & M.H. Cullen. (1991). A case of spontaneous regression of metastatic testicular teratoma. Clinical Oncology. 3(1). 46–48. 2 indexed citations
16.
Freeman, Andrew & M.H. Cullen. (1991). ADVANCES IN THE MANAGEMENT OF CYTOTOXIC DRUG-INDUCED NAUSEA AND VOMITING. Journal of Clinical Pharmacy and Therapeutics. 16(6). 411–421. 2 indexed citations
17.
Steel, Andrew, et al.. (1991). A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus. Clinical Oncology. 3(6). 318–322. 6 indexed citations
18.
Woodroffe, C.M., et al.. (1990). Long-term toxicity of chemotherapy for testicular cancer – the cost of cure. British Journal of Cancer. 61(3). 479–484. 71 indexed citations
19.
Cullen, M.H., et al.. (1989). The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. British Journal of Cancer. 60(5). 759–763. 11 indexed citations
20.
O’Brien, Mary & M.H. Cullen. (1988). ARE WE MAKING PROGRESS IN THE MANAGEMENT OF CYTOTOXIC DRUG–INDUCED NAUSEA AND VOMITING?. Journal of Clinical Pharmacy and Therapeutics. 13(1). 19–31. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. D. Fosså Breakdown of academic impact, for papers by Farzana Pashankar Breakdown of academic impact, for papers by Torgeir Wethal Breakdown of academic impact, for papers by Claudio Spinelli Breakdown of academic impact, for papers by Octavio Castillo Breakdown of academic impact, for papers by D. Parker Breakdown of academic impact, for papers by Patton B. Saul Breakdown of academic impact, for papers by Klaus Pietzner Breakdown of academic impact, for papers by Sumeet Bhatia Breakdown of academic impact, for papers by Thomas A. Rozanski
Rankless by CCL
2026